-
公开(公告)号:EP4048285A1
公开(公告)日:2022-08-31
申请号:EP20842021.6
申请日:2020-10-20
申请人: Novartis AG
IPC分类号: A61K31/706 , A61K39/395 , A61P35/02 , C07K16/28
-
公开(公告)号:EP3191126A1
公开(公告)日:2017-07-19
申请号:EP15767682.6
申请日:2015-09-11
申请人: Novartis AG , Lau, Yvonne , Scott, Jeffrey
发明人: LAU, Yvonne , SCOTT, Jeffrey , LEBWOHL, David , PETERS, Malte , LI, Nanxin
IPC分类号: A61K39/395 , A61K31/506 , C07K16/28 , A61P35/00
摘要: A method of treating a cancer in a subject is disclosed, comprising administering to the subject an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is chosen from one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule, and (ii) the second therapeutic agent is LDK378, thereby treating the cancer.
摘要翻译: 公开了用于治疗癌症的包含免疫调节剂和第二治疗剂的组合,其中免疫调节剂是免疫关卡分子或共刺激分子的活化剂的抑制剂或其组合; 且第二治疗剂选自以下一种或多种:1)c-MET抑制剂; 2)CDK4 / 6抑制剂; 3)PI3K抑制剂; 4)BRAF抑制剂; 5)FGFR抑制剂; 6)MEK抑制剂,或7)BCR-ABL抑制剂。 联合疗法可用于治疗或预防癌症状况和/或病症。
-
公开(公告)号:EP3191126B1
公开(公告)日:2020-05-13
申请号:EP15767682.6
申请日:2015-09-11
申请人: Novartis AG , Lau, Yvonne , Scott, Jeffrey
发明人: LAU, Yvonne , SCOTT, Jeffrey , LEBWOHL, David , PETERS, Malte , LI, Nanxin
IPC分类号: A61K39/395 , A61K31/506 , C07K16/28 , A61P35/00
-
-